PMID- 22906903
OWN - NLM
STAT- MEDLINE
DCOM- 20121106
LR  - 20181201
IS  - 0065-2326 (Print)
IS  - 0065-2326 (Linking)
VI  - 47
DP  - 2012
TI  - Antiplatelet therapy in acute coronary syndromes: ticagrelor.
PG  - 64-77
LID - 10.1159/000338055 [doi]
AB  - Ticagrelor is a direct-acting, oral, reversibly binding P2Y(12) receptor 
      antagonist. As a cyclopentyltriazolopyrimidine, ticagrelor represents a new 
      chemical class of agents that do not require metabolic activation and have 
      consistent ability to inhibit platelet aggregation. The phase III PLATO study 
      evaluated ticagrelor compared with clopidogrel in 18,624 patients with acute 
      coronary syndromes, and demonstrated a significant reduction in the risk of death 
      from vascular causes/myocardial infarction (MI)/stroke with ticagrelor (9.8 vs. 
      11.7% with clopidogrel; HR: 0.84; 95% CI: 0.77-0.92; p < 0.001) without a 
      significant increase in PLATO-defined major bleeding (11.6 vs. 11.2%, 
      respectively; p = 0.43). MI and death from vascular causes were separately 
      significantly reduced, and death from any cause and stent thrombosis reductions 
      achieved nominal statistical significance. Ticagrelor showed benefit over 
      clopidogrel in almost all patient subgroups, including patients who had received 
      clopidogrel at randomization, patients with both planned invasive or noninvasive 
      treatment; patients with ST elevation myocardial infarction (STEMI) referred for 
      primary percutaneous coronary intervention, patients with non-STEMI, and patients 
      who underwent bypass surgery. Hence, the PLATO population reflected specifically 
      those patients who would ordinarily receive thienopyridine-based antiplatelet 
      therapy in a clinical setting.
CI  - Copyright (c) 2012 S. Karger AG, Basel.
FAU - Husted, Steen
AU  - Husted S
AD  - Medical Department, Hospital Unit West, Herning, Denmark. steehust@rm.dk
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120809
PL  - Switzerland
TA  - Adv Cardiol
JT  - Advances in cardiology
JID - 0270063
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - GLH0314RVC (Ticagrelor)
RN  - K72T3FS567 (Adenosine)
SB  - IM
MH  - Adenosine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Angioplasty, Balloon, Coronary
MH  - Clinical Trials, Phase III as Topic
MH  - Humans
MH  - Myocardial Ischemia/drug therapy
MH  - Platelet Activation/*drug effects/physiology
MH  - Purinergic P2Y Receptor Antagonists/*pharmacology/*therapeutic use
MH  - Research Design
MH  - Ticagrelor
EDAT- 2012/08/22 06:00
MHDA- 2012/11/07 06:00
CRDT- 2012/08/22 06:00
PHST- 2012/08/22 06:00 [entrez]
PHST- 2012/08/22 06:00 [pubmed]
PHST- 2012/11/07 06:00 [medline]
AID - 000338055 [pii]
AID - 10.1159/000338055 [doi]
PST - ppublish
SO  - Adv Cardiol. 2012;47:64-77. doi: 10.1159/000338055. Epub 2012 Aug 9.